Header

BUY LIFE SCIENCE REPORTS

PharmaVision offers a comprehensive choice of high quality, insightful reports which identify key trends, future innovations, and growth opportunities. Our reports cover the life science arena including pharmaceuticals, healthcare, diagnostics, drug delivery, emerging R&D technologies and consumer nutrition.

FEATURED REPORT

Featured Reports Icon

EpiCast Report: Asthma - Epidemiology Forecast to 2023

Last year the FDA approved 31 NMEs and 19 biologics nearly twice the number last year. Potential blockbusters include melanoma drugs Opidivo (BMS)and Keytruda (Merck), hep C treatment Harvoni (Gilead Sciences) and Ofev (Boehringer Ingelheim) a TKI to treat idiopathic pulmonary fibrosis. 2015 will be an exciting year with a number of game changing products entering the market including 3 more melanoma drugs from Amgen, Merck & Roche, Sanofi’s hypercholesterolemia drug Praluent (alirocamab) and GSK’s Bosatria (mepolizumab) for hard-to-treat asthma. For more details on asthma see ...

FREE WHITE PAPER

Free White Paper

Factors Currently Diving Pharmaceutical Growth in the Middle East

During the last decade the pharmaceutical industry has been looking towards the emerging economies to expand its global footprint and drive future growth. This white paper focuses on the potential opportunities for investment in the Middle East, particularly with respect to Bahrain, Saudi Arabia and the United Arab Emirates.

EVENTS 2015

Events Icon

Stem Cells in Drug Discovery 2015

2nd Jun 2015 - 3rd Jun 2015